ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: admabiologics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2023 | $5.00 | Strong Buy | Raymond James |
| 10/13/2022 | $5.00 | Buy | Mizuho |
| 11/11/2021 | $5.00 | Outperform → Strong Buy | Raymond James |
| 11/9/2021 | $4.50 | Overweight | Cantor Fitzgerald |
| 10/26/2021 | $6.00 → $5.00 | Outperform | Raymond James |
| 8/12/2021 | $7.00 → $6.00 | Buy | HC Wainwright & Co. |
| 7/6/2021 | $10.00 → $7.00 | Buy | HC Wainwright & Co. |